Capital Advantage’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Capital Advantage’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-5,351	Closed	-$288K	–	70
2014 Q3	$288K	Hold	5,351	–	–	0.15%	42
2014 Q2	$280K	Hold	5,351	–	–	0.15%	40
2014 Q1	$283K	Hold	5,351	–	–	0.2%	34
2013 Q4	$214K	Buy	+5,351	New	+$211K	0.14%	41

Other funds holding TEVA

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Advantage's TEVA Position: Q4 2014 in Review

Capital Advantage sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2014, closing a stake of 5,351 shares — an estimated $288K sold.

Capital Advantage first reported a position in TEVA in Q4 2013 and held it in 4 quarters. The position peaked at $288K in Q3 2014. 822 funds tracked by Wall St. Rank hold TEVA as of Q4 2014.

Capital Advantage reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2014 after selling out during the quarter.
Capital Advantage sold 5,351 Teva Pharmaceutical Industries Limited shares in Q4 2014, an estimated $288K.
Capital Advantage first reported a position in Teva Pharmaceutical Industries Limited in Q4 2013 and held it in 4 quarters.
Capital Advantage's Teva Pharmaceutical Industries Limited position peaked at $288K in Q3 2014.
822 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2014.

Based on Capital Advantage's 13F filing for Q4 2014, filed 15 May 2015.